Nanoplatform strategy for multimodal cancer therapy and tumor visualization

Announcing a new publication for Acta Materia Medica journal. Treatment of cancer can be challenging, because of the disease's intricate and varied nature. Consequently, developing nanomedicines with multimodal therapeutic capabilities for precise tumor therapy holds substantial promise in advancing cancer treatment.

Herein, a nanoplatform strategy involving supramolecular photosensitizers (ETSCe6 NPs) and chelated metal ions (Au and Bi) was found to induce a shift in tumor microenvironment responsiveness from photothermal therapy to photodynamic therapy, thus facilitating tumor visualization for precise diagnosis and treatment. Self-assembly of supramolecular photosensitizers enhanced photothermal therapy through aggregation-caused quenching. Moreover, glutathione triggered disulfide bond cleavage, and consequently Ergosterol (ET) and Chlorin e6 release.

Therefore, chemotherapy and photodynamic therapy achieved synergistic anticancer effects. Ce6 cavities were also used to chelate high valence Au and Bi metal ions for computed tomography. The ETSCe6@Au, Bi NPs demonstrated remarkable efficacy in vitro and in vivo, achieving complete tumor elimination after treatment.

This integrated approach combining imaging, chemotherapy, photodynamic, and photothermal therapies has substantial promise for clinical applications, and may provide an innovative strategy for developing intelligent nanomedicines with promising prospects.

Source:
Journal reference:

Fu, S., et al. (2025) Natural supramolecular photosensitizer with in situ switchable photothermal/photodynamic effects as an imaging platform for precise and controlled cancer synergistic therapy. Acta Materia Medica. doi.org/10.15212/AMM-2024-0081.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New mRNA technique targets disease cells while sparing healthy ones